Pelthos Therapeutics Inc. · AMEX:PTHS
Pelthos Therapeutics — Chromocell Therapeutics — Investor Presentation (July 2024)
25 slides from Pelthos Therapeutics's investor presentation, Jul 29, 2024
Slide 1: Potential Breakthrough Drug for Non-Opioid Pain Treatment Therapies
CHROMOCELL THERAPEUTICS CORPORATION 1 CHROMOCELL THERAPEUTICS CORPORATION Potential Breakthrough Drug for Non-Opioid Pain Treatment Therapies
Slide 2: Forward-looking statements
CHROMOCELL THERAPEUTICS CORPORATION 2 This presentation of Chromocell Therapeutics Corporation (“we”, “us”, “our” or the “Company”) contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “anticipate,” “believe
Slide 3: Corporate Profile: Key data points
CHROMOCELL THERAPEUTICS CORPORATION 3 Key data points (as of 6/24/24, except where noted) Founded 2002 NYSE American Ticker CHRO Stock Price $1.30 Shares Outstanding Fully Diluted ~5.8M Cash, Cash Equivalents (as of 3/31/24) ~$3.8M Total Debt (as of 3/31/24) ~$1.5M Investment to Date >$40M IPO 2024
Slide 4: Investment highlights
CHROMOCELL THERAPEUTICS CORPORATION 4 EXPERIENCED TEAM MILESTONES DEVELOPMENT PROGRAMS NOVEL PAIN THERAPEUTIC INTELLECTUAL PROPERTY LARGE COMMERCIAL OPPORTUNITY COMMERCIALIZATION Novel, peripherally restricted, NaV1.7 receptor target does not penetrate the CNS or cause euphoria and addresses indicat
Slide 5: Management Team
CHROMOCELL THERAPEUTICS CORPORATION 5 Management Team Frank Knuettel | CEO & Chief Financial Officer Mr. Knuettel has 30 years of management experience in growing early-stage companies. He has raised more than $300 million via venture, public equity and debt offerings and managed more than 15 merger
Slide 6: Clinical & Competitive Background
CHROMOCELL THERAPEUTICS CORPORATION 6 CHROMOCELL THERAPEUTICS CORPORATION Clinical & Competitive Background
Slide 7: Sodium Channels (NaVs) and Pain
CHROMOCELL THERAPEUTICS CORPORATION 7 Sodium channels, excitability of primary sensory neurons, and the molecular basis of pain NaV1.1 NaV1.2 NaV1.6 NaV1.8 NaV1.9 NaV1.7 NaV1.5 NaV1.4 Sodium Channels (NaVs) and Pain Pain Perception Sodium channels play a crucial role in pain transmission. • Action p
Slide 8: Why NaV1.7 is a Good Target for Pain Treatment
CHROMOCELL THERAPEUTICS CORPORATION 8 Insensitivity to Pain Lack of NaV1.7 (Rare condition initially described in a family from Pakistan) Severe Pain Excessive NaV1.7 activity (e.g. Erythromelalgia) Congenital Insensitivity to Pain Spectrum of NaV1.7 Activity Severe Pain Why NaV1.7 is a Good Target
Slide 9: NaV Sodium Channels Development for Pain
CHROMOCELL THERAPEUTICS CORPORATION 9 NaV Sodium Channels Development for Pain 2004 2006 2015 2016-2019 2021 2024 Erythromelalgia – the first human disorder linked to an ion channel mutation w/ chronic neuropathic pain linking to SCN9A gene - published in the Journal of Medical Genetics Waxman’s lab
Slide 10: CC8464 – Development Status
CHROMOCELL THERAPEUTICS CORPORATION 10 Preclinical • Potent (nM) inhibitor of human NaV1.7; Subtype selective • Demonstrated in vivo efficacy in several rodent models of pain: Acute, chronic neuropathic, inflammatory, visceral and post-surgical • No CNS and muscle/motor dysfunction effects CMC • Dru
Slide 11: Key milestones position Chromocell for near term value generation
CHROMOCELL THERAPEUTICS CORPORATION 11 Key milestones position Chromocell for near term value generation 2024E 2025E 2026E 2027E Activity Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 CC8464 ISFN & EM Dosing study for ISFN & EM Phase 2 – ISFN Phase 3 trial – only 1 trial required for approval EM - Fast track
Slide 12: Development Plan – Systemic Chronic Pain
CHROMOCELL THERAPEUTICS CORPORATION 12 CHROMOCELL THERAPEUTICS CORPORATION Development Plan – Systemic Chronic Pain
Slide 13: Phase 1 Results and Dose Escalation Study
CHROMOCELL THERAPEUTICS CORPORATION 13 Phase 1 Results • No significant dose related trends or apparent differences compared to placebo in laboratory assessments, vital signs or ECG and no dose escalation stopping criteria were met • A moderate drug-induced rash in 6 of 159 subjects (4%), was the on
Slide 14: Idiopathic Small Fiber Neuropathy: Symptoms and Background
CHROMOCELL THERAPEUTICS CORPORATION 14 Symptoms and Background Most such cases present in adults ≥50 years of age and progress slowly over months to years. The symptoms are typically sensory, involving paresthesia, numbness, or pain. Electrodiagnostic studies show a primarily axonal polyneuropathy.
Slide 15: Phase 2a POC Small Fiber Neuropathy: Strategy and Endpoints
CHROMOCELL THERAPEUTICS CORPORATION 15 Strategy and Endpoints Our strategy sets two key goals for POC studies with CC8464: • Obtain results demonstrating that CC8464 is a viable therapeutic for EM patients • Demonstrate that CC8464 and its blockage of NaV1.7 is a viable therapeutic option in patient
Slide 16: Erythromelalgia Overview
CHROMOCELL THERAPEUTICS CORPORATION 16 Symptoms Erythema (heat), Pain (Usually severe burning pain but may include pins and needles or itching), Swelling, Change in perspiration and discoloration Types of EM Primary EM (Inherited or Sporadic SCN9A mutations + non genetic or uncharacterized) or Secon
Slide 17: Phase 2a Pilot EM Proof of Concept Study
CHROMOCELL THERAPEUTICS CORPORATION 17 An open label study of CC8464 in the treatment of Erythromelalgia • N = approximately 10 (current plan, may be adjusted) • Flare induction after each dose • Primary endpoint is reduction of pain during flare • Secondary endpoints include additional pain endpoin
Slide 18: Development Plan – Eye Pain
CHROMOCELL THERAPEUTICS CORPORATION 18 CHROMOCELL THERAPEUTICS CORPORATION Development Plan – Eye Pain
Slide 19: Eye Pain
CHROMOCELL THERAPEUTICS CORPORATION 19 Eye pain is common with both acute and chronic etiologies that include: Corneal Induced Chronic Pain from Dry Eye/NOP, Post PRK surgery, second eye cataract surgery, acute corneal abrasion, Ectropion/ Entropion, Acute closed angle glaucoma, Uveitis, Iritis/Scle
Slide 20: Eye Pain Treatment Program Plan
CHROMOCELL THERAPEUTICS CORPORATION 20 Strategy • Develop an eye drop formula with CC-8464 with initial 3-month stability • Demonstrate ophthalmologic safety in rabbits • Consider animal efficacy model or progress immediately to a POC trial in humans Potential model for POC Study • Demonstrate pain
Slide 21: Board of Directors & Scientific Advisory Board
CHROMOCELL THERAPEUTICS CORPORATION 21 CHROMOCELL THERAPEUTICS CORPORATION Board of Directors & Scientific Advisory Board
Slide 22: Board of Directors
CHROMOCELL THERAPEUTICS CORPORATION 22 Todd Davis | Chairman Mr. Davis is CEO and a member of the Board of Ligand Pharmaceuticals, with 30 years of experience in biopharmaceutical and life sciences. He has been involved in over $3 billion of healthcare financings including growth equity, public equi
Slide 23: Scientific Advisory Board (SAB)
CHROMOCELL THERAPEUTICS CORPORATION 23 Stephen G. Waxman | MD, PhD, Yale School of Medicine, Chairman • Bridget Marie Flaherty Professor of Neurology, Neuroscience, and Pharmacology • Chair, Department of Neurology (1986-2009), Yale University School of Medicine • Director, Center for Neuroscience &
Slide 24: Investment highlights summary
CHROMOCELL THERAPEUTICS CORPORATION 24 EXPERIENCED TEAM MILESTONES DEVELOPMENT PROGRAMS NOVEL PAIN THERAPEUTIC INTELLECTUAL PROPERTY LARGE COMMERCIAL OPPORTUNITY COMMERCIALIZATION Novel, peripherally restricted, NaV1.7 receptor target does not penetrate the CNS or cause euphoria and addresses indica
Slide 25: Contact
CHROMOCELL THERAPEUTICS CORPORATION 25 CHROMOCELL THERAPEUTICS CORPORATION Frank Knuettel II Chief Executive Officer frank@Chromocell.com 303-718-3108 (m) Mike Moyer
Chromocell Therapeutics — Investor Presentation (July 2024) on 6ix